SALT LAKE CITY, UT--(Marketwired - Jul 25, 2017) - Q Therapeutics, Inc., developer of clinical-stage cell therapies for central nervous system (CNS) disease and injury, announced U.S. Food and Drug Administration (FDA) allowance of its Investigational New Drug (IND) application to proceed with a Phase 1/2a clinical trial of Q-Cells® in patients with Transverse Myelitis™.

URL: http://m.marketwired.com/press-release/fda-allows-q-cells-for-first-in-human-transverse-myelitis-trial-2227455.htm